Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 675,000 |
|
|||||
| News | - | ||||||
| Day High | 0.0007 | Low High |
|||||
| Day Low | 0.0006 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Globestar Therapeutics Corporation (PK) | GSTC | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.00015 | -18.75% | 0.00065 | 09:07:41 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0007 | 0.0006 | 0.0007 | 0.0008 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3 | 675,000 | US$ 0.000698 | US$ 471 | - | 0.0004 - 0.00815 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 09:07:41 | 25,000 | US$ 0.00065 | USD |
Globestar Therapeutics Corporation (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 566.98k | 872.27M | 446.54M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Globestar Therapeutics (PK) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/17/2024 | 15:05 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 2/15/2024 | 10:33 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 1/19/2024 | 16:13 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 1/02/2024 | 15:21 | Edgar (US Regulatory) | Form NT 10-K - Notification of inability to timely file Form.. |
| 11/13/2023 | 11:32 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/17/2023 | 15:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 8/14/2023 | 15:31 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GSTC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0007 | 0.0008 | 0.0006 | 0.0007784 | 554,444 | -0.00005 | -7.14% |
| 1 Month | 0.0005 | 0.0008 | 0.0005 | 0.0006629 | 2,040,493 | 0.00015 | 30.00% |
| 3 Months | 0.0023 | 0.0025 | 0.0004 | 0.0006978 | 8,639,070 | -0.00165 | -71.74% |
| 6 Months | 0.0011 | 0.0025 | 0.0004 | 0.0009919 | 10,684,926 | -0.00045 | -40.91% |
| 1 Year | 0.0056 | 0.00815 | 0.0004 | 0.0014397 | 7,808,901 | -0.00495 | -88.39% |
| 3 Years | 0.073 | 0.073 | 0.0004 | 0.0061922 | 5,118,251 | -0.07235 | -99.11% |
| 5 Years | 0.073 | 0.073 | 0.0004 | 0.0061922 | 5,118,251 | -0.07235 | -99.11% |
Globestar Therapeutics (PK) Description
| GlobeStar Therapeutics Corporation ("GlobeStar"), headquartered in Richland, Washington, was incorporated in 2016 and owns breakthrough addition of treatment for Multiple Sclerosis and other neurodegenerative diseases as well other pharmaceuticals and nutraceutical. GlobeStar is a clinical stage pharmaceutical company testing a worldwide patented formulation of 3 drugs previously approved by the FDA. Pre-clinical trials in Italy showed the drug combination was effective in the reduction of MS co-morbidities. GlobeStar is initiating discussions with the FDA on clinical trial design in the U.S. in preparation for FDA submission and approval. |
